1. |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
|
2. |
Sands J, Tammemägi MC, Couraud S, et al. Lung screening benefits and challenges: A review of the data and outline for implementation. J Thorac Oncol, 2021, 16(1): 37-53.
|
3. |
Liao Z, Rivin Del Campo E, Salem A, et al. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer, 2020, 146: 230-235.
|
4. |
Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg, 1975, 70(4): 606-612.
|
5. |
Detterbeck FC, Jones DR, Kernstine KH, et al. Lung cancer. Special treatment issues. Chest, 2003, 123(1 Suppl): 244S-258S.
|
6. |
Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132(3 Suppl): 290S-305S.
|
7. |
Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e369S-e399S.
|
8. |
Suh YJ, Lee HJ, Sung P, et al. A novel algorithm to differentiate between multiple primary lung cancers and intrapulmonary metastasis in multiple lung cancers with multiple pulmonary sites of involvement. J Thorac Oncol, 2020, 15(2): 203-215.
|
9. |
Liu Y, Tang Y, Xue Z, et al. SUVmax Ratio on PET/CT may differentiate between lung metastases and synchronous multiple primary lung cancer. Acad Radiol, 2020, 27(5): 618-623.
|
10. |
Rami-Porta R, Asamura H, Travis WD, et al. Lung cancer: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin, 2017, 67(2): 138-155.
|
11. |
Nicholson AG, Torkko K, Viola P, et al. Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung. J Thorac Oncol, 2018, 13(2): 205-217.
|
12. |
Kim M, Hwang J, Kim KA, et al. Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement. Mod Pathol, 2022, 35(2): 202-209.
|
13. |
Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol, 2009, 33(12): 1752-1764.
|
14. |
Sun W, Feng L, Yang X, et al. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. Hum Pathol, 2018, 81: 261-271.
|
15. |
Chiang CL, Tsai PC, Yeh YC, et al. Recent advances in the diagnosis and management of multiple primary lung cancer. Cancers (Basel), 2022, 14(1): 242.
|
16. |
Zhu D, Cao D, Shen M, et al. Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort. BMC Cancer, 2021, 21(1): 176.
|
17. |
Yang SR, Chang JC, Leduc C, et al. Invasive mucinous adenocarcinomas with spatially separate lung lesions: Analysis of clonal relationship by comparative molecular profiling. J Thorac Oncol, 2021, 16(7): 1188-1199.
|
18. |
Hu C, Zhao L, Liu W, et al. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer, 2021, 9(12): e003773.
|
19. |
Yu F, Peng M, Bai J, et al. Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules. Int J Cancer, 2022, 151(11): 2020-2030.
|
20. |
Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol, 2019, 14(5): 844-856.
|
21. |
Takahashi Y, Shien K, Tomida S, et al. Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Sci, 2018, 109(11): 3634-3642.
|
22. |
Guo W, Zhou B, Bie F, et al. Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer. Clin Transl Med, 2023, 13(10): e1453.
|
23. |
Goodwin D, Rathi V, Conron M, et al. Genomic and clinical significance of multiple primary lung cancers as determined by next-generation sequencing. J Thorac Oncol, 2021, 16(7): 1166-1175.
|
24. |
Zheng R, Shen Q, Mardekian S, et al. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer. J Thorac Cardiovasc Surg, 2020, 160(2): e71-e79.
|
25. |
Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: Summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol, 2016, 11(5): 639-650.
|
26. |
上海市医学会胸外科专科分会, 上海市医师协会胸外科医师分会, 普胸外科临床能力促进与提升专科联盟. 多原发早期肺癌诊疗专家共识. 中国胸心血管外科临床杂志, 2022, 29(12): 1545-1553.
|
27. |
Lee DS, LaChapelle C, Taioli E, et al. Second primary lung cancers demonstrate similar survival with wedge resection and lobectomy. Ann Thorac Surg, 2019, 108(6): 1724-1728.
|
28. |
Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl_4): iv1-iv21.
|
29. |
Chen TF, Xie CY, Rao BY, et al. Surgical treatment to multiple primary lung cancer patients: A systematic review and meta-analysis. BMC Surg, 2019, 19(1): 185.
|
30. |
Yang H, Sun Y, Yao F, et al. Surgical therapy for bilateral multiple primary lung cancer. Ann Thorac Surg, 2016, 101(3): 1145-1152.
|
31. |
Hattori A, Takamochi K, Oh S, et al. Prognostic classification of multiple primary lung cancers based on a ground-glass opacity component. Ann Thorac Surg, 2020, 109(2): 420-427.
|
32. |
Zhao K, Xia C, Qiu M, et al. Lobar or sublobar resection for early-stage second primary lung cancer≤3 cm in size: A SEER population-based study. J Cancer Res Clin Oncol, 2023, 149(18): 16679-16690.
|
33. |
Shimada Y, Saji H, Otani K, et al. Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions. Lung Cancer, 2015, 88(2): 174-180.
|
34. |
Shimada Y, Maehara S, Kudo Y, et al. Profiles of lung adenocarcinoma with multiple ground-glass opacities and the fate of residual lesions. Ann Thorac Surg, 2020, 109(6): 1722-1730.
|
35. |
Nie Y, Wang X, Yang F, et al. Surgical prognosis of synchronous multiple primary lung cancer: Systematic review and meta-analysis. Clin Lung Cancer, 2021, 22(4): 341-350.
|
36. |
Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stageⅠnon-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial. Lancet Oncol, 2019, 20(4): 494-503.
|
37. |
Nyman J, Hallqvist A, Lund JÅ, et al. SPACE: A randomized study of SBRT vs. conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol, 2016, 121(1): 1-8.
|
38. |
Nikitas J, DeWees T, Rehman S, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers. Clin Lung Cancer, 2019, 20(2): 107-116.
|
39. |
Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol, 2017, 7(5): 295-301.
|
40. |
Ni Y, Xu H, Ye X. Image-guided percutaneous microwave ablation of early-stage non-small cell lung cancer. Asia Pac J Clin Oncol, 2020, 16(6): 320-325.
|
41. |
Páez-Carpio A, Gómez FM, Isus Olivé G, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: Current state of the art. Insights Imaging, 2021, 12(1): 57.
|
42. |
Huang G, Yang X, Li W, et al. A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: A novel therapy for multiple synchronous ground-glass opacities of the lung. Int J Hyperthermia, 2020, 37(1): 414-422.
|
43. |
Liu B, Ye X. Computed tomography-guided percutaneous microwave ablation: A novel perspective to treat multiple pulmonary ground-glass opacities. Thorac Cancer, 2020, 11(9): 2385-2388.
|
44. |
叶欣, 王俊, 危志刚, 等. 热消融治疗肺部亚实性结节专家共识(2021年版). 中国肺癌杂志, 2021, 24(5): 305-322.
|
45. |
Bao F, Yu F, Wang R, et al. Electromagnetic bronchoscopy guided microwave ablation for early stage lung cancer presenting as ground glass nodule. Transl Lung Cancer Res, 2021, 10(9): 3759-3770.
|
46. |
Nomori H, Yamazaki I, Shiraishi A, et al. Cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen. Eur J Radiol, 2020, 133: 109334.
|
47. |
Mal R, Domini J, Wadhwa V, et al. Thermal ablation for primary and metastatic lung tumors: Single-center analysis of peri-procedural and intermediate-term clinical outcomes. Clin Imaging, 2023, 98: 11-15.
|
48. |
Gao S, Stein S, Petre EN, et al. Micropapillary and/or solid histologic subtype based on pre-treatment biopsy predicts local recurrence after thermal ablation of lung adenocarcinoma. Cardiovasc Intervent Radiol, 2018, 41(2): 253-259.
|
49. |
Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for resected EGFR-mutated stageⅠB-ⅢA non-small-cell lung cancer: Updated results from the phaseⅢrandomized ADAURA trial. J Clin Oncol, 2023, 41(10): 1830-1840.
|
50. |
Zhou D, Yao T, Huang X, et al. Real-world comprehensive diagnosis and "Surgery+X" treatment strategy of early-stage synchronous multiple primary lung cancer. Cancer Med, 2023, 12(12): 12996-13006.
|
51. |
Teng F, Xu J, Wang J, et al. Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. Front Oncol, 202, 13: 1110259.
|
52. |
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med, 2021, 27(8): 1345-1356.
|
53. |
Haratake N, Toyokawa G, Takada K, et al. Programmed death-ligand 1 expression and EGFR mutations in multifocal lung cancer. Ann Thorac Surg, 2018, 105(2): 448-454.
|
54. |
Liu M, He WX, Song N, et al. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg, 2016, 50(5): 909-913.
|
55. |
Xu L, Shi M, Wang S, et al. Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. Front Immunol, 2022, 13: 1009621.
|
56. |
Zhang C, Yin K, Liu SY, et al. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. J Immunother Cancer, 2021, 9(4): e002312.
|